Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iopamidol SCHEMBL7101453 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP2C19HIF1ACYP3A4 | |
| Iopamidol SCHEMBL27781 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP2C19HIF1ACYP3A4 | |
| SCHEMBL22006124 | 0.96 | LMNA (0.92) | LMNASMN1; SMN2CYP2C19HIF1A | |
| Iopamidol SCHEMBL3424448 | 0.96 | LMNA (0.92) | LMNASMN1; SMN2CYP2C19HIF1A | |
| Iopamidol SCHEMBL2140144 | 0.96 | LMNA (0.92) | LMNASMN1; SMN2CYP2C19HIF1ACYP3A4 | |
| SCHEMBL31409203 | 0.95 | LMNA (0.90) | LMNASMN1; SMN2CYP2C19HIF1ACYP3A4 | |
| SCHEMBL7709204 | 0.95 | LMNA (0.90) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL13283626 | 0.95 | LMNA (0.90) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL22661225 | 0.92 | LMNA (0.85) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL15297031 | 0.92 | LMNA (0.84) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090138-A1 | ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108635-A1 | ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4172139-B1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | GE HEALTHCARE AS (NO) | 2025-09-24 | — | — | EP | claimed |
| EP-4313934-B1 | INDUSTRIAL SYNTHESIS OF SERINOL | BRACCO IMAGING SPA (IT) | 2025-05-07 | — | — | EP | claimed |
| US-20220105246-A1 | COMPOSITIONS AND METHODS FOR TREATING THE VERTEBRAL COLUMN | BIOMIMETIC THERAPEUTICS LLC (US) | 2022-04-07 | — | — | US | claimed |
| EP-2975021-B1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2017-07-26 | — | — | EP | claimed |
| EP-1353899-B1 | A PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2016-01-20 | — | — | EP | claimed |
| EP-2975021-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | Bracco Imaging SPA (IT) | 2016-01-20 | — | — | EP | claimed |
| US-20160000972-A1 | COMPOSITIONS AND METHODS FOR TREATING THE VERTEBRAL COLUMN | STRYKER CORPORATION | 2016-01-07 | — | — | US | claimed |
| US-20100183515-A1 | COMPOSITIONS AND METHODS FOR TREATING THE VERTEBRAL COLUMN | STRYKER CORPORATION | 2010-07-22 | — | — | US | claimed |
| WO-2008151193-A1 | COMPOSITIONS AND METHODS FOR TREATING THE VERTEBRAL COLUMN | BIOMIMETIC THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | claimed |
| US-7368101-B2 | Process for the preparation of iopamidol and the new intermediates therein | BRACCO IMAGING S.P.A. (IT) | 2008-05-06 | — | — | US | claimed |
| US-20060106253-A1 | Process for the preparation of iopamidol and the new intermediates therein | BRACCO IMAGING S.P.A. (IT) | 2006-05-18 | — | — | US | claimed |
| US-7034183-B2 | Process for the preparation of iopamidol and the new intermediated therein | BRACCO IMAGING S.P.A. (IT) | 2006-04-25 | — | — | US | claimed |
| US-20040082812-A1 | Process for the preparation of iopamidol and the new intermediated therein | BRACCO IMAGING S.P.A. (IT) | 2004-04-29 | — | — | US | claimed |
| EP-0901460-B1 | A PROCESS FOR THE PREPARATION OF 5-AMINO-2,4,6-TRIIODO-1,3-BENZENEDICARBOXYLIC ACID DERIVATIVES | BRACCO IMAGING SPA (IT) | 2002-09-18 | — | — | EP | claimed |
| US-4192859-A | MEDICAL DIAGNOSIS USING X-RAYS | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | claimed |
| US-20260144748-A1 | POLYOL-BASED MULTI-FUNCTIONAL COMPOUNDS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-4192859-A | MEDICAL DIAGNOSIS USING X-RAYS | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | disclosed |
| US-4192859-A | MEDICAL DIAGNOSIS USING X-RAYS | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106253-A1 | Process for the preparation of iopamidol and the new intermediates therein | C9, CBR3, INSR | LMNA 1160/4885SMN1; SMN2 4416/4885CYP2C19 411/4885 |
| US-20040082812-A1 | Process for the preparation of iopamidol and the new intermediated therein | INSR, ACVRL1, CBR3 | LMNA 1132/4885SMN1; SMN2 3859/4885CYP2C19 493/4885 |
| US-20260144748-A1 | POLYOL-BASED MULTI-FUNCTIONAL COMPOUNDS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME | CD44, PAM, PLOD3 | LMNA 3220/4885SMN1; SMN2 3264/4885CYP2C19 1961/4885 |
| US-20260108635-A1 | ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM | BRDT, ILK, KLK3 | LMNA 3855/4885SMN1; SMN2 3806/4885CYP2C19 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.